Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Murphy Andrew J sold 4,147 Regeneron Pharmaceuticals, Inc. shares (Form 4)
Traded Oct 13 to Oct 14, 2026 · Filed Oct 15, 2026
From Oct 13 to Oct 14, 2026, Murphy Andrew J (Co-Chief Scientific Officer) sold 4,147 Regeneron Pharmaceuticals, Inc. shares at an average US$772.70 for US$3.2M under a trading plan, leaving 47,833 shares. Filed Oct 15, 2026 (Form 4).
- Sold
- 4,147 shares
- Price
- US$772.70 average (US$753.76 to US$781.47)
- Value
- US$3.2M
- Holding after
- 47,833 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Co-Chief Scientific Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 13, 2026 | Common Stock | Option exercise | 17,000 | US$381.92 | 64,833 | Direct |
| Oct 13, 2026 | Common Stock | Shares withheld for tax | 12,853 | US$754.58 | 51,980 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 6 | US$753.76 | 51,974 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 35 | US$755.91 | 51,939 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 16 | US$757.68 | 51,923 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 24 | US$758.16 | 51,899 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 14 | US$759.96 | 51,885 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 74 | US$760.65 | 51,811 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 27 | US$761.36 | 51,784 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 55 | US$762.57 | 51,729 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 25 | US$763.76 | 51,704 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 219 | US$764.40 | 51,485 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 271 | US$765.39 | 51,214 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 279 | US$766.47 | 50,935 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 192 | US$767.39 | 50,743 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 105 | US$768.33 | 50,638 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 127 | US$769.30 | 50,511 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 12 | US$770.20 | 50,499 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 283 | US$771.56 | 50,216 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 211 | US$772.56 | 50,005 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 224 | US$773.40 | 49,781 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 121 | US$774.48 | 49,660 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 376 | US$775.46 | 49,284 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 66 | US$776.31 | 49,218 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 38 | US$777.76 | 49,180 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 454 | US$778.64 | 48,726 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 380 | US$779.59 | 48,346 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 463 | US$780.63 | 47,883 | Direct |
| Oct 14, 2026 | Common Stock | Sale | 50 | US$781.47 | 47,833 | Direct |
Source
Download original · View original at SEC